 The 28-day clinical outcomes data from the open-label treatment protocol with mavrilimumab are described in a manuscript by De Luca et al1 entitled, GM-CSF Blockade with Mavrilimumab in Severe COVID-19 Pneumonia and Systemic Hyperinflammation: A Single-Centre, Prospective Cohort Study, which can be accessed online at the following link: The data published in The Lancet Rheumatology are supportive of further development of mavrilimumab in COVID-19 pneumonia, said John F. Paolini, MD, PhD, Chief Medical Officer of Kiniksa. 